Skip to main content
Media RelationsInvestor RelationsHome
Logo SphingotecLogo Sphingotec

Scientific Publications

SphingoTec's biomarker discovery is based on the highest standard of evidence, with over 100 publications, over 100 clinical studies, and more than 100.000 patients enrolled. Browse our scientific publications to learn more about how our biomarkers can impact patient care. You can use filters to narrow your search results by Year, Biomarker and Indications.

2022 bio-ADM Sepsis Other

Can Acute Care Biomarkers change Patient´s Management in Spepsis?

View the paper
2022 DPP3 Cardiovascular Disease Sepsis Other

Safety and tolerability of non‑neutralizing adrenomedullin antibody adrecizumab (HAM8101) in septic shock patients: the AdrenOSS‑2 phase 2a biomarker‑guided trial

View the paper
2022 bio-ADM penKid Sepsis Other

30 Days Mortality Prognostic Value of POCT Bio-Adrenomedullin and Proenkephalin in Patients with Sepsis in the Emergency Department

View the paper
2022 bio-ADM DPP3 Sepsis

Identifying clinical subtypes in sepsis-survivors with different one-year outcomes: a secondary latent class analysis of the FROG-ICU cohort

View the paper
2022 DPP3 Cardiogenic Shock Sepsis Other

The emerging role of dipeptidyl peptidase 3 in pathophysiology

View the paper
2022 bio-ADM Sepsis Other

Bioactive adrenomedullin in sepsis patients in the emergency department is associated with mortality, organ failure and admission to intensive care

View the paper
2022 bio-ADM DPP3 Sepsis

Identifying clinical subtypes in sepsis-survivors with diferent one-year outcomes: a secondary latent class analysis of the FROG-ICU cohort

View the paper
2022 bio-ADM Sepsis Other

Can Acute Care Biomarkers Change Patient’s Management in Sepsis?

View the paper
2022 penKid Acute Kidney Injury Sepsis Other

Advances in the study of subclinical AKI biomarkers

View the paper
2021 penKid Sepsis Other

Plasma proenkephalin A 119-159 on intensive care unit admission is a predictor of organ failure and 30-day mortality

View the paper
2021 DPP3 Sepsis Other

Circulating dipeptidyl peptidase 3 on intensive care unit admission is a predictor of organ dysfunction and mortality

View the paper
2021 DPP3 Sepsis

Monitoring circulating dipeptidyl peptidase 3 (DPP3) predicts improvement of organ failure and survival in sepsis: a prospective observational multinational study

View the paper
2020 bio-ADM DPP3 Sepsis

Promotion of vascular integrity in sepsis through modulation of bioactive adrenomedullin and dipeptidyl peptidase 3

View the paper
2020 penKid Acute Kidney Injury Sepsis

Incidence and outcome of sub-clinical acute kidney injury using penKid in critically ill patients

View the paper
2020 penKid Sepsis

Proenkephalin compared to conventional methods to assess kidney function in critically ill sepsis patients

View the paper
2020 penKid Sepsis

Proenkephalin predicts organ failure, renal replacement therapy, and mortality in patients with sepsis

View the paper
2020 bio-ADM Sepsis

Circulating bioactive adrenomedullin as a marker of sepsis, septic shock and critical illness

View the paper
2020 bio-ADM penKid Acute Kidney Injury Sepsis

The value of plasma pro-enkephalin and adrenomedullin for the prediction of sepsis-associated acute kidney injury in critically ill patients

View the paper
2020 bio-ADM Sepsis

Added value of serial bio-adrenomedullin measurement in addition to lactate for the prognosis of septic patients admitted to ICU

View the paper
2019 penKid Sepsis

Proenkephalin a 119–159 (penKid) – a novel biomarker for acute kidney injury in sepsis: an observational study

View the paper
2019 bio-ADM Sepsis

Circulating biologically active adrenomedullin predicts organ failure and mortality in sepsis

View the paper
2018 penKid Sepsis

Proenkephalin A 119-159 (Penkid) is an early biomarker of septic acute kidney injury: the kidney in sepsis and septic shock (Kid-SSS) study

View the paper
2018 penKid Sepsis

Circulating proenkephalin, acute kidney injury, and its improvement in patients with severe sepsis or shock

View the paper
2018 bio-ADM Sepsis

Circulating adrenomedullin estimates survival and reversibility of organ failure in sepsis: the prospective observational multinational Adrenomedullin and Outcome in Sepsis and Septic Shock-1 (AdrenOSS-1) study

View the paper
2018 bio-ADM Sepsis

Vascular effects of adrenomedullin and the anti-adrenomedullin antibody Adrecizumab in sepsis

View the paper
2018 bio-ADM Sepsis

Adrenomedullin and adrenomedullin-targeted therapy as treatment strategies relevant for sepsis

View the paper
2017 penKid Sepsis

Proenkephalin, neutrophil gelatinase-associated lipocalin, and estimated glomerular filtration rates in patients with sepsis

View the paper
2017 bio-ADM Sepsis

Circulating biologically active adrenomedullin (bio-ADM) predicts hemodynamic support requirement and mortality during sepsis

View the paper
2016 bio-ADM Sepsis

Plasma adrenomedullin in critically ill patients with sepsis after major surgery: a pilot study

View the paper
2015 pro-ENK Sepsis

Diagnostic and short-term prognostic utility of plasma proenkephalin (pro-ENK) for acute kidney injury in patients admitted with sepsis in the emergency department

View the paper
2014 bio-ADM Sepsis

Plasma adrenomedullin is associated with short-term mortality and vasopressor requirement in patients admitted with sepsis

View the paper